Immunotherapy, e.g., immune checkpoint blockade (ICB) therapy and chimeric antigen receptor (CAR) T cell therapy, has brought about revolutionary changes in cancer treatment and has been incorporated into treatment guidelines for various cancer types.[3] One research area of immunotherapy is identifying targets that may trigger or enhance anti‐tumor immune responses, e.g., the stimulator of interferon genes (STING)[4] STING plays a pivotal role as a signaling molecule in orchestrating the innate immune response within the body. This evidence concerns the gene STING1 and neoplasm.